Trump signs executive order to expand research into psychedelic treatment for PTSD

President Donald Trump signed an executive order Saturday morning at the White House that could reshape how the U.S. approaches mental health treatment for PTSD. The order directs the Department of Health and Human Services, the NIH, and the FDA to facilitate and fund new research into ibogaine, a naturally occurring psychedelic compound used in some countries to help people struggling with trauma and substance use disorders.

Ibogaine is not approved for medical use in the United States and remains a Schedule I controlled substance, meaning it's classified as having a high potential for abuse and no accepted medical use. But in clinics abroad-from Mexico to South Africa-some patients have turned to it as a last resort. Early reports suggest it may interrupt addiction cycles and provide deep psychological insights, though the treatment carries risks, including heart complications and, in rare cases, death.

The Trump administration has framed the order as a win for veterans and others who haven't responded to traditional therapies. Sources close to the decision say the president was influenced by meetings with military families and advocacy groups pushing for innovation in mental health care. The order stops short of legalizing ibogaine but creates a pathway for federally supported clinical trials, which could eventually lead to regulatory approval.

Reaction has been mixed. Some medical researchers welcome the push for data, stressing that stigma has long blocked serious study of psychedelics. Others urge caution, noting that ibogaine can cause dangerous changes in heart rhythm and should not be used without strict medical oversight. The American Psychiatric Association has called for rigorous trials before any expansion of access.

The signing event marked a rare focus on public health from an administration better known for tax cuts and immigration enforcement. It also comes just weeks before Trump's scheduled trip to China, where health and science cooperation may be on the table. Some analysts see the move as part of a broader effort to position the U.S. as a leader in next-generation medical innovation.

While the order itself is narrow, it signals a shift in how Washington is thinking about mental health. A growing number of states have already begun exploring psychedelic-assisted therapies, and federal interest could accelerate that trend. For now, ibogaine remains unavailable through legal U.S. channels-but that could change if research under this new directive yields promising results.

Trump, speaking briefly before signing, called the moment "a breakthrough for American healing" and said the country shouldn't ignore treatments that are helping people elsewhere. "If it works in other places, why aren't we looking? That's what science is for," he said.